Skip to main content

Astrazeneca PLC 6-K, filed Nov 16, 2026

Astrazeneca PLC (AZN)

6-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 6-K

Astrazeneca PLC filed this 6-K on November 16, 2026.

AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk. AI summary